Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2006-07-11
2006-07-11
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S141100, C424S142100, C424S143100, C424S144100, C424S152100, C424S153100, C424S172100, C424S173100, C424S085100, C424S085400, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C530S389100, C530S389600, C530S351000, C514S885000, C514S903000
Reexamination Certificate
active
07074403
ABSTRACT:
Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.
REFERENCES:
patent: 5484892 (1996-01-01), Tedder et al.
patent: 5593676 (1997-01-01), Bhat et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 5795967 (1998-08-01), Aggarwal et al.
patent: 6051228 (2000-04-01), Aruffo et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 0 332 865 (1989-02-01), None
patent: 91/13974 (1991-09-01), None
patent: 94/27638 (1994-12-01), None
patent: 99/54440 (1999-10-01), None
patent: WO 00/67796 (2000-11-01), None
The Merck Manual of Diagnosis and Therapy (Seventeenth Edition, Beers et al. eds., Merck Research Laboratories, Whitehouse Station, NJ, 1999; Chapter 180 “Demyelinating Diseases”, pp. 1474-1476.
Leung et al. Mol. Immunol. 1995; 32(17/18):1413-1427
Todd D. Levine et al., “IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab.”, Neurology, vol. 52, No. 8, pp. 1701-1704, May 12, 1999, XP-000942610.
A. Protheroe et al., “Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma.”, Rheumatology, vol. 38, No. 11, pp. 1150-1152, Nov., 1999, XP-000942661.
Zhengzing Qu et al., “Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates.”, Journal of Immunological Methods, vol. 213, No. 2, pp. 131-144, Apr. 15, 1998, XP-0002103672.
W. Rowan et al., “Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B-and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.”, Immunology, vol. 95, No. 3, pp. 427-436, Nov., 1998, XP-000942636.
Rhona Stein et al., “Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2.”, Cancer Immunology Immunotherapy, vol. 37, No. 5, pp. 293-298, 1993, XP-002070322.
Statmatios Theocharis et al., “Characterization of in Vivo Mutated T Cell Clones from Patients with Systemic Lupus Erythematosus1.”, Clinical Immunology and Immunopathology, vol. 74, No. 2, pp. 135-142, Feb., 1995, XP-000942609.
Pawlak-Byczkowska, et al.,Two New Monoclonal Antibodies, EPB-1 and EPB-2, Reactive With Human Lymphoma; Cancer Research: 49, No. 16, 4568-4577, (1989).
Shih, et al.,Internalization and Intracellular Processing Of An Anti-B-Cell Lymphoma Monoclonal Antibody, LL2: Int. J. Cancer: 56, 538-545, (1994).
Leung, et al.,Chimerization of LL2, a Rapidly Internalizing Antibody Specific For B Cell Lymphoma; HYBRIDOMA: 13, No. 6, 469-476, (1994).
Ghetie, et al.,Evaluation of Ricin A Chain-Containing Immunotoxins Directed Against CD19 and CD22 Antigens On Normal and Malignant Human B-Cells As Potential Reagents For In Vico Therapy; Cancer Research: 48, No. 9, 2313-2634, (1988).
Hekman, et al.,Initial Experience With Treatment Of Human B Cell Lymphoma With Anti-CD19 Monoclonal Antibody; Cancer Immunology Immunotherapy; 32, 364-372, (1991).
Kaminski, et al.,Radioimmunotherapy of B-Cell Lymphoma With [1311] Anti-B1(Anti-CD20)Antibody; The New England Journal of Medicine: 329, No. 7, 459-465, (1993).
Press, et al.,Radiolabeled-Antibody Therapy Of B-Cell Lymphoma With Autologous Bone Marrow Support; The New England Journal of Medicine: 329, No. 17, 1219-1224, (1993).
Maloney, et al.,Phase I Clinical Trial Using Escalating Single-Dose Infusion Of Chimeric Anti-CD20 Monoclonal Antibody(IDEC-C2B8)In Patients With Recurrent B-Cell Lymphoma; Journal of the American Society of Hematology: 84, No. 8, 2457-2466, (1994).
Press et al.,Phase II Trial of131I-B1(anti-CD20)Antibody Therapy With Autologous Stem Cell Transplantation For Relapsed B Cell Lymphomas; The Lancet: 346, No. 8971, 336-340, (1995).
Longo,Immunotherapy For Non-Hodgkin's Lymphoma; Current Opinion in Oncology: 8, No. 5, 353-359, (1996).
Hess et al., “Specificity of Effector T Lymphocytes in Autologous Graft-Versus-Host Disease: Role of the Major Histocompatibility Complex Class II Invariant Chain Peptide”, Blood, Mar. 1997, pp. 2203-2209, vol. 89, No. 6.
Goldenberg David M.
Hansen Hans J.
Faegre & Benson LLP
Gambel Phillip
Immunomedics Inc.
Ouspenski Ilia
LandOfFree
Immunotherapy of autoimmune disorders using antibodies which... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotherapy of autoimmune disorders using antibodies which..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapy of autoimmune disorders using antibodies which... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3552931